RecruitingRecurrent Respiratory Papillomatosis
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Clinically confirmed diagnosis of recurrent respiratory papillomatosis.
- ✓ Patients with papillomas in the laryngeal mucosa at the time of recruitment and patients with records of recurrent papillomas in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment. NOTE: The presence of papillomas in laryngeal mucosa or clinical records of the presence of papillomas in laryngeal mucosa is required.
- ✓ Human papilloma virus (HPV)6+ RRP in larynx
- ✓ ECOG (Eastern cooperative oncology group performance test) performance status 0 or 1 (Appendix I).
- ✓ The following laboratory values obtained ≤ 28 days prior to apheresis.
- ✓ Absolute neutrophil count (ANC) ≥1.0 x 109 /L
- ✓ Platelet count (PLT) ≥ 75 x 109 /L
- ✓ Hemoglobin ≥ 8.5 g/dL
You may not qualify if…
- ✕ Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
- ✕ Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy.
- ✕ Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- ✕ Receiving any other approved or investigational agent (including immune checkpoint blockers, immune modulators, and therapeutic vaccine models) for recurrent respiratory papillomatosis patients which would be considered as a treatment for the papillomas in laryngeal mucosa ≤ 6 months prior to study enrollment.
- ✕ Other active malignancy ≤ 5 years prior to enrollment. NOTE: If there is a history or prior malignancy, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, they must not be receiving other specific treatment for their cancer within one year.
- ✕ History of unstable heart disease including myocardial infarction ≤ 6 months prior to registration, congestive heart failure requiring use of ongoing maintenance therapy, significant cardiac dysfunction (left ventricular injection fraction 24 hours) documented by repeated measurement ≤ 4 weeks prior to registration
- ✕ Diagnosis of autoimmune disease, including, but not limited to, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
- ✕ Use of a systemic steroid (\> 5 mg prednisone daily or equivalent) ≤ 4 weeks prior to registration.
Where it's recruiting
Arizona
Scottsdale
Source: ClinicalTrials.gov · NCT07317154 · last updated 2026-04-03